Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will publish its third-quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. The company will hold a conference call and live webcast at 8:00 a.m. ET the same day. Participants must register in advance to receive a local or toll-free phone number and personal PIN. The webcast will be available through Teva's investor-relations website, with a replay posted within 24 hours after the call. Teva describes its business as a leading innovative biopharmaceutical company supported by a global generics operation, with activities spanning neuroscience, immunology, complex generic medicines, biosimilars (highly similar versions of biological medicines) and pharmacy brands. The release cautions that the conference-call presentation may contain forward-looking statements subject to known and unknown risks, including competition, execution of its Pivot to Growth strategy, pipeline expansion, commercialization, portfolio management, organizational transformation, cost savings, indebtedness, business operations, compliance, regulatory and litigation matters, and broader financial and economic risks.